JP2017536414A5 - - Google Patents

Info

Publication number

JP2017536414A5

JP2017536414A5 JP2017545861A JP2017545861A JP2017536414A5 JP 2017536414 A5 JP2017536414 A5 JP 2017536414A5 JP 2017545861 A JP2017545861 A JP 2017545861A JP 2017545861 A JP2017545861 A JP 2017545861A JP 2017536414 A5 JP2017536414 A5 JP 2017536414A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

seq

acid sequence

amino acid

vegf

Prior art date

2015-11-19

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 20
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 14
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 14
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 14
• 125000003275 alpha amino acid group Chemical group 0.000 claims 10
• 239000005557 antagonist Substances 0.000 claims 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
• 239000000427 antigen Substances 0.000 claims 4
• 102000036639 antigens Human genes 0.000 claims 4
• 108091007433 antigens Proteins 0.000 claims 4
• 239000012634 fragment Substances 0.000 claims 4
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 208000035475 disorder Diseases 0.000 claims 3
• 208000030533 eye disease Diseases 0.000 claims 3
• 239000003112 inhibitor Substances 0.000 claims 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
• 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 2
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 2
• 229920001213 Polysorbate 20 Polymers 0.000 claims 2
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 2
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
• 150000001413 amino acids Chemical class 0.000 claims 2
• 239000000539 dimer Substances 0.000 claims 2
• 239000007951 isotonicity adjuster Substances 0.000 claims 2
• 239000012669 liquid formulation Substances 0.000 claims 2
• 239000002736 nonionic surfactant Substances 0.000 claims 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
• 229920001184 polypeptide Polymers 0.000 claims 2
• 229940068977 polysorbate 20 Drugs 0.000 claims 2
• 102000004196 processed proteins & peptides Human genes 0.000 claims 2
• 108090000765 processed proteins & peptides Proteins 0.000 claims 2
• 208000004644 retinal vein occlusion Diseases 0.000 claims 2
• 239000011780 sodium chloride Substances 0.000 claims 2
• 239000001488 sodium phosphate Substances 0.000 claims 2
• 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
• 239000003381 stabilizer Substances 0.000 claims 2
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
• 230000002792 vascular Effects 0.000 claims 2
• 206010059245 Angiopathy Diseases 0.000 claims 1
• 102000009075 Angiopoietin-2 Human genes 0.000 claims 1
• 108010048036 Angiopoietin-2 Proteins 0.000 claims 1
• 102000009840 Angiopoietins Human genes 0.000 claims 1
• 108010009906 Angiopoietins Proteins 0.000 claims 1
• 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
• 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
• 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
• 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
• 108060003951 Immunoglobulin Proteins 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
• 229930006000 Sucrose Natural products 0.000 claims 1
• 108091008605 VEGF receptors Proteins 0.000 claims 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
• 229960002833 aflibercept Drugs 0.000 claims 1
• 108010081667 aflibercept Proteins 0.000 claims 1
• 206010064930 age-related macular degeneration Diseases 0.000 claims 1
• 239000000872 buffer Substances 0.000 claims 1
• 239000006172 buffering agent Substances 0.000 claims 1
• 201000005667 central retinal vein occlusion Diseases 0.000 claims 1
• 201000011190 diabetic macular edema Diseases 0.000 claims 1
• 102000018358 immunoglobulin Human genes 0.000 claims 1
• 239000007924 injection Substances 0.000 claims 1
• 238000002347 injection Methods 0.000 claims 1
• 208000002780 macular degeneration Diseases 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 230000009826 neoplastic cell growth Effects 0.000 claims 1
• 210000001210 retinal vessel Anatomy 0.000 claims 1
• 230000007928 solubilization Effects 0.000 claims 1
• 238000005063 solubilization Methods 0.000 claims 1
• 239000005720 sucrose Substances 0.000 claims 1
• 125000000185 sucrose group Chemical group 0.000 claims 1